The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -12,599,569 |
| Depreciation and amortization | 21,715 |
| Stockbased compensation | 478,141 |
| Issuance of common stock to consultants | 39,050 |
| Foreign currency loss (gain) | -95,319 |
| Prepaid expenses and other current and noncurrent assets | 217,906 |
| Accounts payable | -646,701 |
| Accrued expenses | -64,488 |
| Net cash used in operating activities | -12,894,439 |
| Proceeds from the exercise of warrants | 91 |
| Proceeds from issuance of common stock | 5,047,606 |
| Common stock issuance costs | 407,459 |
| Net cash provided by financing activities | 4,640,238 |
| Change in cash, cash equivalents and restricted cash | -8,254,201 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 4,679 |
| Cash, cash equivalents and restricted cash-beginning of year | 22,890,055 |
| Cash, cash equivalents and restricted cash-end of period | 14,640,533 |
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. (APRE)